Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792583 | 1.00 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1733236 | 1.00 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30496259 | 0.98 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL12524261 | 0.91 | MEN1 (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2226544 | 0.91 | MEN1 (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL4934881 | 0.91 | MEN1 (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL25079350 | 0.90 | HPGD (0.55) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1965735 | 0.89 | USP2 (0.61) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL16893310 | 0.87 | CHRM2 (0.46) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL12384323 | 0.86 | NR1H2 (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070273-A | Novel process for the preparation of (3R) -fluoropyrrolidine hydrochloride | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025087822-A1 | NEW PROCESS FOR THE PREPARATION OF (3R)-FLUOROPYRROLIDINE HYDROCHLORIDE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-01 | — | — | WO | disclosed |
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024138486-A1 | TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4169575-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | Sato Pharmaceutical Co., Ltd. (JP) | 2023-04-26 | — | — | EP | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| WO-2022140428-A2 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | ELI LILLY AND COMPANY | 2007-08-23 | — | — | US | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | HPGD 3576/4885RECQL 3424/4885EPHX1 3662/4885 |
| US-20070197604-A1 | Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses | HCRTR1, HRH3, HCRTR2 | HPGD 1930/4885RECQL 3272/4885EPHX1 604/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | HPGD 178/4885RECQL 1455/4885EPHX1 1640/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | HPGD 260/4885RECQL 2849/4885EPHX1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.